Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 836 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at... September 3, 2026 Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas... January 26, 2026 A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... July 11, 2024 President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... February 3, 2022 Load more HOT NEWS Can I Have a Non-Violent Relationship with Cancer (Part 2) Latest episode of our podcast for cancer researchers 关于肺癌生物标志物检测应当了解的信息：专家问答 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin
